INCIDENCE OF ANEJACULATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA RECEIVING SILODOSIN 8mg - A PROSPECTIVE STUDY

Introduction:Silodosin, a selective α1A-adrenoceptor blocker, improves Lower Urinary Tract Symptoms (LUTS) in Benign Prostatic Hyperplasia (BPH) by relaxing smooth muscle in the prostate and bladder neck. Its receptor specificity, however, predisposes patients to ejaculatory dysfunction, particularly Anejaculation, which may affect compliance. This study aimed to determine the region-specific incidence and characterize the pattern of ejaculatory changes in Sexually active men receiving Silodosin 8 mg daily for BPH.Methods:A prospective, questionnaire-based descriptive study was conducted at the Institute of Urology, Madras Medical College–Rajiv Gandhi Government General Hospital, Chennai ,India, from December 2023 to May 2024. Sixty-six sexually active men with a clinical diagnosis of BPH, newly initiated on Silodosin 8 mg once daily, were enrolled. Data on demographic profile, perception of ejaculatory change, frequency, and type of dysfunction, compliance to treatment were obtained using a structured questionnaire.Results:Most participants were 55–60 years old (63.6%). Overall, 95.5% reported an ejaculatory change, of which 80.3% experienced it with every sexual act. Anejaculation was observed in 22.7% of patients, while 72.7% reported reduced ejaculate volume. Regarding treatment adherence, 65.1% continued therapy without interruption, 24.2% continued despite concerns, and only 6.0% discontinued due to ejaculatory dysfunction.Conclusion:Silodosin 8 mg is frequently associated with ejaculatory dysfunction, with anejaculation occurring in 22.7% of sexually active men. Despite these side effects, most patients continued therapy, highlighting the importance of counselling about potential sexual adverse events to support adherence and informed decision-making.